Amedisys
(NASDAQ:AMED)
$91.82
0.14[0.15%]
At close: Jun 14
$91.82
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$101.00
Lowest Price Target1
$101.00
Consensus Price Target1
$123.38

Amedisys (NASDAQ:AMED) Stock, Analyst Ratings, Price Targets, Predictions

Amedisys Inc has a consensus price target of $123.38, established from looking at the 82 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, RBC Capital, and Cantor Fitzgerald on April 25, 2024, March 25, 2024, and September 14, 2023. With an average price target of $100.67 between Cantor Fitzgerald, RBC Capital, and Cantor Fitzgerald, there's an implied 9.63% upside for Amedisys Inc from these 3 analyst ratings.

Analyst Trends and Forecast
1
1
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.7
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
Raymond James
RBC Capital
TD Cowen
Credit Suisse

1calculated from analyst ratings

Analyst Ratings for Amedisys

Buy NowGet Alert
04/25/2024Buy Now10%Cantor Fitzgerald
Sarah James
→ $101ReiteratesNeutral → NeutralGet Alert
03/26/2024Buy NowRaymond James
John Ransom
MaintainsMarket PerformGet Alert
03/25/2024Buy Now8.91%RBC Capital
Ben Hendrix
$97 → $100MaintainsOutperformGet Alert
09/14/2023Buy Now10%Cantor Fitzgerald
Sarah James
$100 → $101MaintainsNeutralGet Alert
07/31/2023Buy Now10%TD Cowen
Gary Taylor
$84 → $101MaintainsMarket PerformGet Alert
07/27/2023Buy Now10%Credit Suisse
Jonathan Yong
→ $101ReiteratesNeutral → NeutralGet Alert
07/06/2023Buy Now10%Jefferies
Brian Tanquilut
$98 → $101DowngradeBuy → HoldGet Alert
06/28/2023Buy NowBenchmark
Bill Sutherland
DowngradeBuy → HoldGet Alert
06/27/2023Buy NowBenchmark
Bill Sutherland
DowngradeBuy → HoldGet Alert
06/27/2023Buy Now10%Truist Securities
David Macdonald
$97 → $101MaintainsHoldGet Alert
06/07/2023Buy Now5.64%Truist Securities
David Macdonald
→ $97DowngradeBuy → HoldGet Alert
06/06/2023Buy Now8.91%Cantor Fitzgerald
Sarah James
$91 → $100MaintainsNeutralGet Alert
06/06/2023Buy Now25.25%Benchmark
Bill Sutherland
→ $115ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now8.91%Credit Suisse
Jonathan Yong
$115 → $100DowngradeOutperform → NeutralGet Alert
05/08/2023Buy Now-8.52%TD Cowen
Gary Taylor
$95 → $84MaintainsMarket PerformGet Alert
05/05/2023Buy Now-4.16%Barclays
Steve Valiquette
$93 → $88MaintainsEqual-WeightGet Alert
05/04/2023Buy Now5.64%Truist Securities
David Macdonald
$115 → $97MaintainsBuyGet Alert
05/04/2023Buy Now12.18%Stephens & Co.
Scott Fidel
→ $103Reiterates → Equal-WeightGet Alert
04/21/2023Buy Now-5.25%Cantor Fitzgerald
Sarah James
→ $87Initiates → NeutralGet Alert
04/13/2023Buy Now25.25%Truist Securities
David Macdonald
$130 → $115MaintainsBuyGet Alert
03/14/2023Buy Now25.25%Benchmark
Bill Sutherland
→ $115Reiterates → BuyGet Alert
03/14/2023Buy Now12.18%Stephens & Co.
Scott Fidel
→ $103Reiterates → Equal-WeightGet Alert
03/13/2023Buy Now1.29%Barclays
Steve Valiquette
→ $93Initiates → Equal-WeightGet Alert
02/27/2023Buy Now25.25%Credit Suisse
Jonathan Yong
→ $115Reiterates → OutperformGet Alert
02/21/2023Buy Now20.89%RBC Capital
Ben Hendrix
$114 → $111MaintainsOutperformGet Alert
02/16/2023Buy Now3.46%Stephens & Co.
Scott Fidel
→ $95Reiterates → Equal-WeightGet Alert
02/16/2023Buy Now25.25%Benchmark
Mark Miller
$120 → $115MaintainsBuyGet Alert
02/13/2023Buy Now30.69%Benchmark
Bill Sutherland
→ $120Reiterates → BuyGet Alert
01/25/2023Buy Now30.69%Benchmark
Bill Sutherland
$135 → $120MaintainsBuyGet Alert
01/23/2023Buy Now25.25%Credit Suisse
Jonathan Yong
$140 → $115MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Amedisys (AMED) stock?

A

The latest price target for Amedisys (NASDAQ:AMED) was reported by Cantor Fitzgerald on April 25, 2024. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 10.00% upside). 10 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Amedisys (AMED)?

A

The latest analyst rating for Amedisys (NASDAQ:AMED) was provided by Cantor Fitzgerald, and Amedisys reiterated their neutral rating.

Q

When was the last upgrade for Amedisys (AMED)?

A

The last upgrade for Amedisys Inc happened on March 1, 2022 when UBS raised their price target to $168. UBS previously had a sell for Amedisys Inc.

Q

When was the last downgrade for Amedisys (AMED)?

A

The last downgrade for Amedisys Inc happened on July 6, 2023 when Jefferies changed their price target from $98 to $101 for Amedisys Inc.

Q

When is the next analyst rating going to be posted or updated for Amedisys (AMED)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.

Q

Is the Analyst Rating Amedisys (AMED) correct?

A

While ratings are subjective and will change, the latest Amedisys (AMED) rating was a reiterated with a price target of $0.00 to $101.00. The current price Amedisys (AMED) is trading at is $91.82, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch